Skip to main navigation
Skip to search
Skip to main content
Pure University (For Demo Only) Home
Help & FAQ
English
中文
Home
Profiles
Research units
Research output
Equipment
Datasets
Activities
Prizes
Impacts
Projects
Press/Media
Search by expertise, name or affiliation
Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis
John D. Fisk
Neuroscience
Research output
:
Contribution to journal
›
Article
›
peer-review
7
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Mathematics
Covariate
100%
Cox Proportional Hazards Model
100%
Hazard Ratio
100%
Healthcare
100%
Logistic Regression Model
100%
Median
100%
Keyphrases
Clinically Isolated Syndrome
8%
Multiple Sclerosis Care
8%
Starting Platform
8%
Teriflunomide
8%
Therapy Persistence
8%
Time to Discontinuation
16%
Immunology and Microbiology
Clinically Isolated Syndrome
11%
Fumaric Acid Dimethyl Ester
11%
Teriflunomide
11%
Medicine and Dentistry
Clinically Isolated Syndrome
8%
Fumaric Acid Dimethyl Ester
8%
Glatiramer
8%
Teriflunomide
8%
Pharmacology, Toxicology and Pharmaceutical Science
Teriflunomide
7%